Verastem | VSTM - Operating Expenses

Stock Price
6.09
Daily Change
-0.44 -6.67%
Monthly
12.89%
Yearly
-13.57%
Q2 Forecast
6.44

Verastem reported $59.01M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Alaunos Therapeutics USD 1.19M 148K Sep/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Curis USD 9.02M 23.01M Dec/2025
Cytokinetics USD 196.12M 27.43M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Laboratory Of America USD 3.13B 32.4M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025
Verastem USD 59.01M 21.98M Dec/2025